Lung Trials

A list of our early phase lung cancer trials which are open to recruitment at University College London Hospitals.

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.

Additional early phase clinical trials recruiting Lung cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.

APL-101-01 Safety and efficacy of APL-101 in NSCLC and advanced solid tumors: Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
IRAS Number:	273024
Principal Investigator:	Prof. Martin Forster
Drug Class/ Treatment:	APL-101 (C-Met Inhibitor)
Patient Population:	Non-Small Cell Lung Cancer (NSCLC)
Trial Hosted By - UCLH Clinical Research Facility (CRF)

KisMET-01 (MYTX-011-01) A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-DrugConjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer - KisMET-01
IRAS Number:	1007533
Principal Investigator:	Dr Sarah Benafif
Drug Class/Treatment:	MYTX-011 (cMET-Targeted Valine-Citrulline Monomethyl Auristain E (vcMMAE) ADC)
Patient Population:	Non-Small Cell Lung Cancer (NSCLC)
Trial Hosted By - UCLH Clinical Research Facility (CRF)

LuCa-MERIT-1 (BNT116-01) LuCa-MERIT-1: First-in-human, open label, Phase I dose confirmation trial evaluating the safety, tolerability and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
IRAS Number:	1008928
Principal Investigator:	Dr Sarah Benafif
Drug Class/Treatment:	BNT116 (mRNA Vaccine) Monotherapy and Combination with Immunotherapies
Patient Population:	Non-Small Cell Lung Cancer (NSCLC)
Trial Hosted By - UCLH Clinical Research Facility (CRF)

PALOMA-2 A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
IRAS Number:	1006215
Principal Investigator:	Dr Sarah Benafif
Drug Class/ Treatment:	Amivantamab (Bi-specific EGF & MET Receptor-Directed Antibody) Subcutaneous
Patient Population:	Non-Small Cell Lung Cancer (NSCLC): Cohorts 1, 3, 5, and 6 - EGFR Exon19del or Exon 21 L858R mutation Cohort 2 - EGFR Exon20ins mutation
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

CONCORDE A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer
IRAS Number:	282001
Principal Investigator:	Dr. Crispin Hiley
Drug Class/ Treatment:	Radiotherapy + Olaparib (PARP Inhibitor) or AZD1390 (Oral ATM Inhibitor)
Patient Population:	Non-Small Cell Lung Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

On-hold to recruitment

CCR4220: HyPeR Hyper: A Phase 1, Dose Escalation Study Of SGI-110, A Second-Generation Hypo-Methylating Agent In Combination With Pembrolizumab (MK3475) In Patients With Refractory Solid Tumors
IRAS Number:	201385
Principal Investigator:	Dr. Dionysis Papadatos-Pastos
Drug Class/Treatment:	ASTX727 (Fixed-dose combination of Decitabine and Cedazuridine) + Pembrolizumab
Patient Population:	Refractory Solid Tumours: NSCLC patients
Trial Hosted By - UCLH Clinical Research Facility (CRF)